1 |
Tao S, Cao F, Sam NB, Li H, Feng Y, Ni J, Wang P, Li X, Pan H. Dickkopf-1 as a promising therapeutic target for autoimmune diseases. Clinical Immunology 2022;245:109156. [DOI: 10.1016/j.clim.2022.109156] [Reference Citation Analysis]
|
2 |
Omran A, Atanasova D, Landgren F, Magnusson P. Sclerostin: From Molecule to Clinical Biomarker. Int J Mol Sci 2022;23:4751. [PMID: 35563144 DOI: 10.3390/ijms23094751] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
3 |
Pan S, Cesarek M, Godoy C, Co CM, Schindler C, Padilla K, Haskell A, Barreda H, Story C, Poole R, Dabney A, Gregory CA. Morpholino-driven blockade of Dkk-1 in osteosarcoma inhibits bone damage and tumour expansion by multiple mechanisms. Br J Cancer. [DOI: 10.1038/s41416-022-01764-z] [Reference Citation Analysis]
|
4 |
Tong X, Yu D, Yu L, Chen W, Wen Y, Gu P. Exploring the role of monocyte chemoattractant protein-1 in fibroblast-like synovial cells in rheumatoid arthritis. PeerJ 2021;9:e11973. [PMID: 34447637 DOI: 10.7717/peerj.11973] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|